Affitech Appoints Sergej Kiprijanov New Head of Research
Posted on: Wednesday, 13 February 2008, 03:00 CST
The human antibody company, Affitech AS, announced today the appointment of Dr. Sergej Kiprijanov as the Vice President of Discovery Research and Preclinical Development. Joining Affitech at a key stage in the company's growth, Dr. Kiprijanov brings a wealth of experience in the antibody therapeutic field. Previously CSO of Novoplant GmbH, a German plant biotech company developing antibodies for oral applications, Dr. Kiprijanov was also Head of Research with Affimed Therapeutics AG in Heidelberg, Germany, focusing on engineering human antibodies and antibody fragments for cancer indications.
Welcoming the appointment, Affitech CEO Dr. Martin Welschof said, "Dr. Kiprijanov brings the experience and skillset Affitech requires as we start to improve our extremely promising MBAS and CBAS technologies and develop our product candidates. We are indeed delighted to have Sergej join our R&D team. I have known Sergej since he was a researcher at the German Cancer Research Center (DKFZ), Heidelberg, Germany, playing a key role in creating novel bispecific antibody formats for use in tumor therapy. He has generated an impressive number of publications and patents in the antibody field from his work both in the technology area as well as in development of antibody product candidates."
Prior to moving to Germany, Dr. Kiprijanov headed the Laboratory of Cellular Engineering at the Russian State Research Center of Virology and Biotechnology "Vector" (Novosibirsk, Russia). Dr. Kiprijanov graduated in Biochemistry and Molecular Biology from Novosibirsk State University (Novosibirsk, Russia) in 1983 and received his Ph.D. degree from the Institute of Genetics and Selection of Industrial Microorganisms (Moscow, Russia) in 1990. Dr. Kiprijanov has authored more than 60 research articles, reviews and book chapters and is named as an inventor on 20 patents and patent applications.
Source: Business Wire
Related Articles
- Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
- BIO International Convention 2009: Research Location Germany Presents Potential in Regenerative Medicine
- BioWa Licenses POTELLIGENT(R) Technology to Major Pharmaceutical Company for Use in Antibody Research and Development
- Eusa Pharma Divests Antibody Research Business
- EUSA Pharma Divests Monoclonal Antibody Research Business and Early-Stage Oncology Product
- Affitech Signs Antibody Research and Licensing Agreement With Roche
- UCB Licenses BioWa's POTELLIGENT(R) Technology for Use in Antibody Research and Development
- Antibody Research Helped By Grant Program
- Ball State research team to travel to Russia for space study
 |
 |
User Comments (0)
RSS Feeds